In the first quarter of 2026, BiomX completed a fundamental strategic overhaul, halting all clinical trials, winding down its U.S. phage unit and exiting its legacy biotech operations after its former core subsidiary, BiomX Ltd., entered insolvency in Israel in December 2025. The company replaced its entire management team and board, installed a new CEO and CFO, and adopted an acquisition-led strategy to build a diversified defense and security technology platform.

BiomX now controls three main subsidiaries: DFSL, which offers high-accuracy LADAR-based counter‑UAS and perimeter detection systems; Zorronet, which provides AI-driven security and command-and-control middleware; and X Security & Defense, which is being funded to develop distribution for aerial firefighting and first-response technologies. Zorronet has already secured pilots and classified projects with Elbit and Rafael and signed distribution deals in the U.S., Mexico, the UAE and Israel, positioning the group for early revenue, though much of its near-term income will depend on a handful of defense-related customers.

The company’s transformation comes with sizable risks, including limited operating history in defense markets, dependence on successful integration of acquisitions, customer concentration and heavy exposure to Israeli regulatory and geopolitical conditions. It is also working to address a March 25, 2026 non-compliance notice from NYSE American tied to stockholders’ equity, while managing potential dilution from warrants and convertible securities and navigating volatile regional security, export controls and supply-chain pressures that could affect operations and growth.